Candriam Luxembourg SCA Continues to Hold Position in Pharmerica Corporation (PMC)

Cornelia Mascio
Agosto 12, 2017

New York State Teachers Retirement System continued to hold its stake in shares of PharMerica Co.

Candriam Luxembourg S.C.A. held its stake in shares of Pharmerica Corporation (NYSE:PMC) during the second quarter, according to its most recent disclosure with the SEC. US Bancorp DE now owns 7,121 shares of the company's stock worth $167,000 after buying an additional 2,081 shares in the last quarter. AQR Capital Management LLC owned approximately 0.25% of PharMerica worth $1,768,000 as of its most recent filing with the SEC.

Several hedge funds and other institutional investors have recently bought and sold shares of PMC. US Bancorp DE increased its stake in PharMerica by 41.3% in the first quarter. First Trust Advisors LP increased its stake in PharMerica by 82.5% in the first quarter. Louisiana State Employees Retirement System now owns 12,500 shares of the company's stock worth $293,000 after buying an additional 100 shares in the last quarter. JPMorgan Chase & Co. raised its stake in PharMerica by 6.5% in the first quarter. Comerica Bank now owns 38,381 shares of the company's stock worth $912,000 after buying an additional 5,608 shares in the last quarter. SG Americas Securities LLC purchased a new stake in PharMerica during the first quarter valued at $121,000. Pharmerica Corporation has a 1-year low of $19.20 and a 1-year high of $29.10.

Pharmerica Corporation (NYSE:PMC) opened at 29.10 on Friday. The company had a trading volume of 346,427 shares. The stock has a market capitalization of $904.07 million, a PE ratio of 39.36 and a beta of 0.92. The firm has a 50 day moving average of $26.64 and a 200-day moving average of $24.94.

PharMerica (NYSE:PMC) last released its earnings results on Wednesday, August 2nd. As of the last earnings report the EPS was $0.74 and is projected to be $1.92 for the current year with 31,121,000 shares presently outstanding. PharMerica had a return on equity of 3.41% and a net margin of 0.79%. The business had revenue of $592 million for the quarter, compared to the consensus estimate of $592.96 million. During the same quarter in the prior year, the company earned $0.47 earnings per share. The value of the total investment in Pharmerica Corporation went from $17,930,000 to $33,027,000 a change of 84.2% since the last quarter. Analysts anticipate that PharMerica will post $1.92 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: "PharMerica Co. (NYSE:PMC)" was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of USA & worldwide trademark & copyright laws. The original version of this report can be viewed at https://www.thestockobserver.com/2017/08/11/aqr-capital-management-llc-raises-position-in-pharmerica-corporation-pmc-updated.html. Zacks Investment Research lowered PharMerica from a "buy" rating to a "hold" rating in a research note on Friday, June 23rd. ValuEngine cut PharMerica from a "buy" rating to a "hold" rating in a report on Friday, June 2nd.

On August 4, 2017 the stock rating was changed to a "Neutral" by Credit Suisse a cut from the previous "Outperform" rating. They noted that the move was a valuation call. Finally, BidaskClub cut PharMerica from a "hold" rating to a "sell" rating in a research note on Monday, July 31st. KeyCorp downgraded shares of PharMerica to an "overweight" rating in a research report on Tuesday. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. Company shares last traded at $29.05 quite a bit higher than $26.52, the stock's 50 day moving average and significantly higher than the 200 day moving average of $24.91.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE